Table 1.

Baseline characteristics of patients with AML undergoing chemotherapy

Variables	Median (range)/number (%)
Total number of patients	200
Age (years)	35 (2–66)
Sex
Male	118 (59%)
Female	82 (41%)
Status of disease
Newly diagnosed	186 (93%)
Relapsed disease	14 (7%)
Chemotherapy regimens
Cytosine/daunorubicin (7/3)	161 (80.5%)
Cytosine/daunorubicin (5/2)	17 (8.5%)
Paediatric BFM	8 (4%)
High dose cytosine, Flag, HAM, others	14 (7%)
Type of antifungal prophylaxis
Posaconazole	178 (89%)
Others (amphotericin B, voriconazole, fluconazole)	22 (11%)